Trials / Not Yet Recruiting
Not Yet RecruitingNCT07136142
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FH-006 for Injection | FH-006 for injection. |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2025-08-22
- Last updated
- 2025-08-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07136142. Inclusion in this directory is not an endorsement.